I was given the heads up by @Gumnut70 in regards to the posters being presented at the AACR Conference in less than 4 weeks
This was what Jackie was referring to in her announcement regarding interim data on Dep Irinotecan
Those intending to attend the American Association for Cancer Research in October will be pleased to know Starpharma are presenting 3 posters
Poster Session A on Thursday, October 12, from 12:30-4 P.M.
Poster Session B on Friday, October 13, from 12:30-4 P.M
Poster Session C on Saturday, October 14 from 12:30-4 P.M.
POSTER SESSION A
A147: A HER2 targeted polylysine dendrimer nanoparticle radiotheranostic demonstrates excellent tumor accumulation, rapid clearance from circulation, and promising performance in PET-CT imaging. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.
Most probably referencing the information released by Starpharma recently. Refer to the two announcements below
POSTER SESSION B
B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111 / DEP irinotecan) in patients with advanced solid tumours. Jia Liu, The Kinghorn Cancer Centre, St Vincent’s Hospital; Garvan Institute of Medical Research; St Vincent’s Clinical School, University of New South Wales, Sydney, Australia.
No doubt referring to announcement recently released by Starpharma below\
POSTER SESSION C
C167: An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy in mouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpoint blockade and PARP inhibition. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)